Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

11/12/24 9:50:11 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $APGE alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 APOGEE THERAPEUTICS INC COMMON STOCK Cusip #03770N101 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #03770N101 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,502,413 Item 6: 0 Item 7: 7,502,482 Item 8: 0 Item 9: 7,502,482 Item 11: 16.672% Item 12: HC Cusip #03770N101 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 7,502,482 Item 8: 0 Item 9: 7,502,482 Item 11: 16.672% Item 12: IN Item 1(a). Name of Issuer: APOGEE THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 221 CRESCENT ST., BUILDING 17, SUITE 102B, Waltham, MA 02453 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 03770N101 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 7,502,482 (b) Percent of Class: 16.672% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 7,502,482 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of APOGEE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of APOGEE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of APOGEE THERAPEUTICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $APGE alert in real time by email

Recent Analyst Ratings for

$APGE

Date	Price Target	Rating	Analyst
5/1/2026	$140.00	Buy	Rothschild & Co Redburn
3/18/2026	$83.00	Hold	Truist
1/22/2026	$83.00	Outperform → Sector Perform	RBC Capital Mkts
1/7/2026		Peer Perform	Wolfe Research
12/17/2025	$95.00	Overweight	Stephens
12/10/2025	$103.00	Buy	Deutsche Bank
11/3/2025	$109.00	Buy	Craig Hallum
10/21/2025	$105.00	Outperform	Mizuho

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

11/12/24 9:50:11 AM ET

$APGE

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $APGE alert in real time by email

Recent Analyst Ratings for

$APGE

Date	Price Target	Rating	Analyst
5/1/2026	$140.00	Buy	Rothschild & Co Redburn
3/18/2026	$83.00	Hold	Truist
1/22/2026	$83.00	Outperform → Sector Perform	RBC Capital Mkts
1/7/2026		Peer Perform	Wolfe Research
12/17/2025	$95.00	Overweight	Stephens
12/10/2025	$103.00	Buy	Deutsche Bank
11/3/2025	$109.00	Buy	Craig Hallum
10/21/2025	$105.00	Outperform	Mizuho

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$APGE

Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$APGE

$APGE
Analyst Ratings

Rothschild & Co Redburn initiated coverage on Apogee Therapeutics with a new price target

Truist initiated coverage on Apogee Therapeutics with a new price target

Apogee Therapeutics downgraded by RBC Capital Mkts with a new price target

$APGE
Insider Trading

Chief Executive Officer Henderson Michael Thomas sold $1,641,711 worth of shares (20,000 units at $82.09) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,115,987 units (SEC Form 4)

Chief Medical Officer Dambkowski Carl exercised 4,125 shares at a strike of $22.86 and sold $462,784 worth of shares (5,500 units at $84.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.66% to 207,023 units (SEC Form 4)

Chief Financial Officer Henderson Jane sold $164,080 worth of shares (2,000 units at $82.04) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 173,371 units (SEC Form 4)

$APGE
SEC Filings

Apogee Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure

Apogee Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

SEC Form 144 filed by Apogee Therapeutics Inc.

$APGE
Press Releases

Apogee Therapeutics to Participate in Upcoming June Conferences

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

$APGE
Insider Purchases

Director Mckenna Mark C. bought $990,775 worth of shares (20,000 units at $49.54) (SEC Form 4)

$APGE
Leadership Updates

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

$APGE
Financials

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

$APGE
Large Ownership Changes